Voorbeelden van het gebruik van Opdivo in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
How does Opdivo work?
OPDIVO contains sodium.
Why is Opdivo approved?
OPDIVO as monotherapy.
Other information about Opdivo.
OPDIVO should not be frozen.
For this use, Opdivo is used on its own.
OPDIVO in combination with ipilimumab.
Serious adverse reactions occurred in 49% of patients receiving Opdivo.
OPDIVO is for intravenous use only.
These side effects were also the most common side effects when Opdivo was used together with ipilimumab.
Opdivo contains the active substance nivolumab.
For squamous NSCLC, a study involving 272 patients showed that patients given Opdivo survived for around 9.2 months,
OPDIVO may be given in combination with ipilimumab.
An additional study in 945 previously untreated advanced melanoma patients investigated Opdivo in combination with ipilimumab,
What OPDIVO looks like and contents of the pack?
Improvements in the time patients lived without their disease getting worse when treated with Opdivo plus ipilimumab relative to Opdivo used on its own were only seen for patients whose cancer cells produced low levels of PD-L1.
OPDIVO must be stored in a refrigerator 2°C to 8°C.
The company will also provide further data on the long-term benefits of Opdivo and carry out analyses to try to identify which patients are most likely to benefit from treatment with the medicine.
OPDIVO 10 mg/mL concentrate for solution for infusion.
Supportive information was also provided from another study indicating that Opdivo could produce a response in patients with squamous NSCLC whose disease had progressed despite several previous treatments.
OPDIVO can be used for intravenous administration either.
The average survival with Opdivo was around 12.2 months,
OPDIVO must not be administered as an intravenous push or bolus injection.
In advanced renal cell carcinoma, Opdivo was compared with everolimus in one main study involving 821 patients whose disease advanced despite previous treatment.
OPDIVO should not be infused concomitantly in the same intravenous line with other medicinal products.
To date, the Opdivo clinical development program has enrolled more than 25,000 patients.
Opdivo is available as a concentrate that is made up into a solution for infusion(drip)
To date, the Opdivo clinical development program has enrolled more than 25,000 patients.
Opdivo is also commonly associated with side effects related to the activity of the immune system on body organs.